All News

Sacubitril/Valsartan Not Superior to Valsartan for Advanced Heart Failure
Ref: ACC
Tags: Press ReleaseCongestive Heart Failure Clinical Research (R&D) Medical AffairsACCsacubitril valsartan
Pirfenidone Reduces Scar Tissue in Patients with Heart Failure
Ref: ACC
Tags: Press ReleaseCongestive Heart Failure Clinical Research (R&D) Medical AffairsACCpirfenidone
Stealth BioTherapeutics Announces Additional Development Financing to Advance Elamipretide Clinical Trials
Ref: PR Newswire
Tags: Press ReleaseStealth BioTherapeutics Corporate Affairselamipretide SBT-272
Clinical Trial Suggests Convalescent Plasma May Improve Survival with Severe COVID-19
Ref: Columbia University's Mailman School of Public Health
Tags: Press ReleaseCOVID-19 Clinical Research (R&D)
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session
Ref: Business Wire
Tags: Press ReleasePhaseBio Pharmaceuticals Clinical Research (R&D) Medical AffairsACCdabigatran
Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer
Ref: GlobeNewswire
Tags: People NewsBaxter Calimmune CSL Exelixis J&J Novartis Oncternal Therapeutics PDL BioPharma PMV Pharma Takeda Corporate Affairs
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results
Ref: PR Newswire
Tags: Press ReleaseNeuroBo Pharmaceuticals Corporate Affairs
Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights
Ref: GlobeNewswire
Tags: Press ReleaseCue Biopharma Corporate AffairsCue-101
New Data Presented at American Thoracic Society Meeting Reinforces the Potential of an Oral Drug Combination Therapy for the Treatment of Obstructive Sleep Apnea
Ref: Business Wire
Tags: Press ReleaseApnimedSleep Apnoea Clinical Research (R&D) Medical AffairsATSAD128 reboxetine oxybutynin
Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update
Ref: GlobeNewswire
Tags: Press ReleaseAcer Therapeutics Corporate AffairsACER-001 Edsivo